NO329164B1 - Fremgangsmate for a desorbere, isolere og opparbeide epotiloner og anvendelse av svakt polare eller apolare losemidler for desorpsjon av epotiloner - Google Patents

Fremgangsmate for a desorbere, isolere og opparbeide epotiloner og anvendelse av svakt polare eller apolare losemidler for desorpsjon av epotiloner Download PDF

Info

Publication number: NO329164B1
Authority: NO; Norway
Prior art keywords: epothilones; mixture; epothilone; desorption; resin
Prior art date: 2000-12-07

Application number

NO20032591A

Other languages

English (en)

Norwegian (no)

Other versions

NO20032591L (no

NO20032591D0 (no

Inventor

Ernst Kusters

Heinz Unternahrer

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-12-07

Filing date

2003-06-06

Publication date

2010-09-06

2003-06-06 Application filed by Novartis Ag filed Critical Novartis Ag

2003-06-06 Publication of NO20032591L publication Critical patent/NO20032591L/no

2003-06-06 Publication of NO20032591D0 publication Critical patent/NO20032591D0/no

2010-09-06 Publication of NO329164B1 publication Critical patent/NO329164B1/no

Links

HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical class C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 title claims abstract description 105
229930013356 epothilone Natural products 0.000 title claims abstract description 102
238000000034 method Methods 0.000 title claims abstract description 57
238000003795 desorption Methods 0.000 title claims abstract description 50
239000002798 polar solvent Substances 0.000 title description 4
239000012454 non-polar solvent Substances 0.000 title description 3
HESCAJZNRMSMJG-HGYUPSKWSA-N epothilone A Natural products O=C1[C@H](C)[C@H](O)[C@H](C)CCC[C@H]2O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C HESCAJZNRMSMJG-HGYUPSKWSA-N 0.000 claims abstract description 64
239000002904 solvent Substances 0.000 claims abstract description 56
229920005989 resin Polymers 0.000 claims abstract description 46
239000011347 resin Substances 0.000 claims abstract description 46
QXRSDHAAWVKZLJ-OXZHEXMSSA-N Epothilone B Natural products O=C1[C@H](C)[C@H](O)[C@@H](C)CCC[C@@]2(C)O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C QXRSDHAAWVKZLJ-OXZHEXMSSA-N 0.000 claims abstract description 43
QXRSDHAAWVKZLJ-PVYNADRNSA-N epothilone B Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 QXRSDHAAWVKZLJ-PVYNADRNSA-N 0.000 claims abstract description 43
238000000746 purification Methods 0.000 claims abstract description 8
239000000203 mixture Substances 0.000 claims description 48
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 44
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 39
239000012071 phase Substances 0.000 claims description 27
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical group C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 25
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 25
150000002825 nitriles Chemical class 0.000 claims description 25
150000002148 esters Chemical class 0.000 claims description 22
UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical group C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 claims description 20
150000003883 epothilone derivatives Chemical class 0.000 claims description 20
238000001704 evaporation Methods 0.000 claims description 19
230000008020 evaporation Effects 0.000 claims description 17
150000002430 hydrocarbons Chemical class 0.000 claims description 16
125000000217 alkyl group Chemical group 0.000 claims description 14
125000004432 carbon atom Chemical group C* 0.000 claims description 14
229920003002 synthetic resin Polymers 0.000 claims description 14
239000000057 synthetic resin Substances 0.000 claims description 14
238000000926 separation method Methods 0.000 claims description 13
239000004215 Carbon black (E152) Substances 0.000 claims description 12
239000003849 aromatic solvent Substances 0.000 claims description 12
229930195733 hydrocarbon Natural products 0.000 claims description 12
239000000463 material Substances 0.000 claims description 12
150000001350 alkyl halides Chemical class 0.000 claims description 11
239000000243 solution Substances 0.000 claims description 11
238000004587 chromatography analysis Methods 0.000 claims description 9
238000002425 crystallisation Methods 0.000 claims description 9
230000008025 crystallization Effects 0.000 claims description 9
238000010828 elution Methods 0.000 claims description 9
239000000284 extract Substances 0.000 claims description 8
238000004366 reverse phase liquid chromatography Methods 0.000 claims description 8
239000011877 solvent mixture Substances 0.000 claims description 8
229910052736 halogen Inorganic materials 0.000 claims description 7
150000002367 halogens Chemical class 0.000 claims description 7
PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 claims description 6
125000003545 alkoxy group Chemical group 0.000 claims description 6
239000000725 suspension Substances 0.000 claims description 6
238000005377 adsorption chromatography Methods 0.000 claims description 5
150000001555 benzenes Chemical group 0.000 claims description 5
239000007787 solid Substances 0.000 claims description 5
229920001577 copolymer Polymers 0.000 claims description 4
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 4
239000011541 reaction mixture Substances 0.000 claims description 4
239000012527 feed solution Substances 0.000 claims description 3
239000007788 liquid Substances 0.000 claims description 3
239000008346 aqueous phase Substances 0.000 claims description 2
125000004183 alkoxy alkyl group Chemical group 0.000 claims 1
238000004519 manufacturing process Methods 0.000 abstract description 6
238000010626 work up procedure Methods 0.000 abstract description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 48
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 33
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 30
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 23
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
238000000605 extraction Methods 0.000 description 18
229960004592 isopropanol Drugs 0.000 description 15
-1 epothilones A and B Chemical class 0.000 description 12
238000005191 phase separation Methods 0.000 description 10
230000008901 benefit Effects 0.000 description 8
238000001914 filtration Methods 0.000 description 8
239000001963 growth medium Substances 0.000 description 8
XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 7
229920001429 chelating resin Polymers 0.000 description 7
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 7
238000001179 sorption measurement Methods 0.000 description 7
CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 6
239000000460 chlorine Substances 0.000 description 6
238000004821 distillation Methods 0.000 description 6
JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 6
229940011051 isopropyl acetate Drugs 0.000 description 6
GWYFCOCPABKNJV-UHFFFAOYSA-M isovalerate Chemical compound CC(C)CC([O-])=O GWYFCOCPABKNJV-UHFFFAOYSA-M 0.000 description 6
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
238000002360 preparation method Methods 0.000 description 6
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 5
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 5
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 5
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 5
229910052794 bromium Inorganic materials 0.000 description 5
229910052801 chlorine Inorganic materials 0.000 description 5
229910052731 fluorine Inorganic materials 0.000 description 5
239000011737 fluorine Substances 0.000 description 5
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 5
244000005700 microbiome Species 0.000 description 5
239000000741 silica gel Substances 0.000 description 5
229910002027 silica gel Inorganic materials 0.000 description 5
GWHJZXXIDMPWGX-UHFFFAOYSA-N 1,2,4-trimethylbenzene Chemical compound CC1=CC=C(C)C(C)=C1 GWHJZXXIDMPWGX-UHFFFAOYSA-N 0.000 description 4
CHRJZRDFSQHIFI-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;styrene Chemical compound C=CC1=CC=CC=C1.C=CC1=CC=CC=C1C=C CHRJZRDFSQHIFI-UHFFFAOYSA-N 0.000 description 4
IVSZLXZYQVIEFR-UHFFFAOYSA-N 1,3-Dimethylbenzene Natural products CC1=CC=CC(C)=C1 IVSZLXZYQVIEFR-UHFFFAOYSA-N 0.000 description 4
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
YNQLUTRBYVCPMQ-UHFFFAOYSA-N Ethylbenzene Chemical compound CCC1=CC=CC=C1 YNQLUTRBYVCPMQ-UHFFFAOYSA-N 0.000 description 4
URLKBWYHVLBVBO-UHFFFAOYSA-N Para-Xylene Chemical group CC1=CC=C(C)C=C1 URLKBWYHVLBVBO-UHFFFAOYSA-N 0.000 description 4
238000005119 centrifugation Methods 0.000 description 4
229920006026 co-polymeric resin Polymers 0.000 description 4
RWGFKTVRMDUZSP-UHFFFAOYSA-N cumene Chemical compound CC(C)C1=CC=CC=C1 RWGFKTVRMDUZSP-UHFFFAOYSA-N 0.000 description 4
125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 4
125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 4
229910052739 hydrogen Inorganic materials 0.000 description 4
239000001257 hydrogen Substances 0.000 description 4
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 4
238000003756 stirring Methods 0.000 description 4
WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 3
ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
229920000858 Cyclodextrin Polymers 0.000 description 3
241000863434 Myxococcales Species 0.000 description 3
238000010521 absorption reaction Methods 0.000 description 3
150000001298 alcohols Chemical class 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
239000006227 byproduct Substances 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
239000003480 eluent Substances 0.000 description 3
239000002609 medium Substances 0.000 description 3
239000007790 solid phase Substances 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
239000012485 toluene extract Substances 0.000 description 3
238000011282 treatment Methods 0.000 description 3
230000005526 G1 to G0 transition Effects 0.000 description 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
239000004793 Polystyrene Substances 0.000 description 2
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
150000001335 aliphatic alkanes Chemical class 0.000 description 2
150000004996 alkyl benzenes Chemical class 0.000 description 2
RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
238000009835 boiling Methods 0.000 description 2
QARVLSVVCXYDNA-UHFFFAOYSA-N bromobenzene Chemical compound BrC1=CC=CC=C1 QARVLSVVCXYDNA-UHFFFAOYSA-N 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 2
238000011109 contamination Methods 0.000 description 2
125000004122 cyclic group Chemical group 0.000 description 2
JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 2
238000009826 distribution Methods 0.000 description 2
238000003810 ethyl acetate extraction Methods 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
239000000706 filtrate Substances 0.000 description 2
238000005187 foaming Methods 0.000 description 2
239000012535 impurity Substances 0.000 description 2
125000002346 iodo group Chemical group I* 0.000 description 2
238000002955 isolation Methods 0.000 description 2
239000007791 liquid phase Substances 0.000 description 2
230000014759 maintenance of location Effects 0.000 description 2
239000011159 matrix material Substances 0.000 description 2
AUHZEENZYGFFBQ-UHFFFAOYSA-N mesitylene Substances CC1=CC(C)=CC(C)=C1 AUHZEENZYGFFBQ-UHFFFAOYSA-N 0.000 description 2
125000001827 mesitylenyl group Chemical group [H]C1=C(C(*)=C(C([H])=C1C([H])([H])[H])C([H])([H])[H])C([H])([H])[H] 0.000 description 2
238000002156 mixing Methods 0.000 description 2
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
BDERNNFJNOPAEC-UHFFFAOYSA-N n-propyl alcohol Natural products CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
239000005445 natural material Substances 0.000 description 2
150000002894 organic compounds Chemical class 0.000 description 2
HFPZCAJZSCWRBC-UHFFFAOYSA-N p-cymene Chemical compound CC(C)C1=CC=C(C)C=C1 HFPZCAJZSCWRBC-UHFFFAOYSA-N 0.000 description 2
XNLICIUVMPYHGG-UHFFFAOYSA-N pentan-2-one Chemical compound CCCC(C)=O XNLICIUVMPYHGG-UHFFFAOYSA-N 0.000 description 2
229920002223 polystyrene Polymers 0.000 description 2
150000003254 radicals Chemical class 0.000 description 2
238000001953 recrystallisation Methods 0.000 description 2
HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
238000004062 sedimentation Methods 0.000 description 2
239000000126 substance Substances 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
239000008096 xylene Substances 0.000 description 2
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
238000005160 1H NMR spectroscopy Methods 0.000 description 1
AXPZDYVDTMMLNB-UHFFFAOYSA-N Benzyl ethyl ether Chemical compound CCOCC1=CC=CC=C1 AXPZDYVDTMMLNB-UHFFFAOYSA-N 0.000 description 1
NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 1
238000005481 NMR spectroscopy Methods 0.000 description 1
229930012538 Paclitaxel Natural products 0.000 description 1
241000276498 Pollachius virens Species 0.000 description 1
241001532577 Sorangium Species 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000002156 adsorbate Substances 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
150000005224 alkoxybenzenes Chemical class 0.000 description 1
230000001093 anti-cancer Effects 0.000 description 1
230000003466 anti-cipated effect Effects 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
YCOXTKKNXUZSKD-UHFFFAOYSA-N as-o-xylenol Natural products CC1=CC=C(O)C=C1C YCOXTKKNXUZSKD-UHFFFAOYSA-N 0.000 description 1
239000011324 bead Substances 0.000 description 1
230000001851 biosynthetic effect Effects 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
238000011210 chromatographic step Methods 0.000 description 1
230000000536 complexating effect Effects 0.000 description 1
238000010668 complexation reaction Methods 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
239000013078 crystal Substances 0.000 description 1
239000012228 culture supernatant Substances 0.000 description 1
150000004292 cyclic ethers Chemical class 0.000 description 1
150000003997 cyclic ketones Chemical class 0.000 description 1
229940097362 cyclodextrins Drugs 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
238000010586 diagram Methods 0.000 description 1
MHDVGSVTJDSBDK-UHFFFAOYSA-N dibenzyl ether Chemical compound C=1C=CC=CC=1COCC1=CC=CC=C1 MHDVGSVTJDSBDK-UHFFFAOYSA-N 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
MYRTYDVEIRVNKP-UHFFFAOYSA-N divinylbenzene Substances C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 1
239000000386 donor Substances 0.000 description 1
238000001035 drying Methods 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
239000006260 foam Substances 0.000 description 1
238000009472 formulation Methods 0.000 description 1
238000005194 fractionation Methods 0.000 description 1
239000000499 gel Substances 0.000 description 1
238000005227 gel permeation chromatography Methods 0.000 description 1
239000011521 glass Substances 0.000 description 1
231100000086 high toxicity Toxicity 0.000 description 1
239000000852 hydrogen donor Substances 0.000 description 1
PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
SNHMUERNLJLMHN-UHFFFAOYSA-N iodobenzene Chemical compound IC1=CC=CC=C1 SNHMUERNLJLMHN-UHFFFAOYSA-N 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
238000003760 magnetic stirring Methods 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
239000000401 methanolic extract Substances 0.000 description 1
239000002032 methanolic fraction Substances 0.000 description 1
UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
PYLWMHQQBFSUBP-UHFFFAOYSA-N monofluorobenzene Chemical compound FC1=CC=CC=C1 PYLWMHQQBFSUBP-UHFFFAOYSA-N 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
229960001592 paclitaxel Drugs 0.000 description 1
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
DLRJIFUOBPOJNS-UHFFFAOYSA-N phenetole Chemical compound CCOC1=CC=CC=C1 DLRJIFUOBPOJNS-UHFFFAOYSA-N 0.000 description 1
229920005990 polystyrene resin Polymers 0.000 description 1
239000011148 porous material Substances 0.000 description 1
239000000047 product Substances 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
IHIUATGHXSTFND-UHFFFAOYSA-N propan-2-yl acetate;toluene Chemical compound CC(C)OC(C)=O.CC1=CC=CC=C1 IHIUATGHXSTFND-UHFFFAOYSA-N 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
239000012508 resin bead Substances 0.000 description 1
238000004007 reversed phase HPLC Methods 0.000 description 1
125000006413 ring segment Chemical group 0.000 description 1
238000002390 rotary evaporation Methods 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
238000010898 silica gel chromatography Methods 0.000 description 1
239000007858 starting material Substances 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
230000009897 systematic effect Effects 0.000 description 1
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
RCINICONZNJXQF-XAZOAEDWSA-N taxol® Chemical compound O([C@@H]1[C@@]2(CC(C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3(C21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-XAZOAEDWSA-N 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
238000010977 unit operation Methods 0.000 description 1
239000003643 water by type Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
Silicon Polymers (AREA)
Saccharide Compounds (AREA)

NO20032591A 2000-12-07 2003-06-06 Fremgangsmate for a desorbere, isolere og opparbeide epotiloner og anvendelse av svakt polare eller apolare losemidler for desorpsjon av epotiloner NO329164B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0029895.0A GB0029895D0 (en)	2000-12-07	2000-12-07	Organic compounds
PCT/EP2001/014771 WO2002046196A1 (en)	2000-12-07	2001-12-05	Process for the isolation and purification of epothilones

Publications (3)

Publication Number	Publication Date
NO20032591L NO20032591L (no)	2003-06-06
NO20032591D0 NO20032591D0 (no)	2003-06-06
NO329164B1 true NO329164B1 (no)	2010-09-06

Family

ID=9904660

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20032591A NO329164B1 (no)	2000-12-07	2003-06-06	Fremgangsmate for a desorbere, isolere og opparbeide epotiloner og anvendelse av svakt polare eller apolare losemidler for desorpsjon av epotiloner

Country Status (31)

Country	Link
US (2)	US6946561B2 (pl)
EP (1)	EP1345944B1 (pl)
JP (1)	JP4287650B2 (pl)
KR (1)	KR100894990B1 (pl)
CN (1)	CN1263761C (pl)
AR (1)	AR031902A1 (pl)
AT (1)	ATE292132T1 (pl)
AU (2)	AU2002224936B2 (pl)
BR (1)	BR0115991A (pl)
CA (1)	CA2433414C (pl)
CZ (1)	CZ301664B6 (pl)
DE (1)	DE60109814T2 (pl)
DK (1)	DK1345944T3 (pl)
EC (1)	ECSP034641A (pl)
ES (1)	ES2239687T3 (pl)
GB (1)	GB0029895D0 (pl)
HU (1)	HU224910B1 (pl)
IL (2)	IL156088A0 (pl)
MX (1)	MXPA03005097A (pl)
MY (1)	MY128409A (pl)
NO (1)	NO329164B1 (pl)
NZ (1)	NZ526197A (pl)
PE (1)	PE20020568A1 (pl)
PL (1)	PL209406B1 (pl)
PT (1)	PT1345944E (pl)
RU (1)	RU2285007C2 (pl)
SI (1)	SI1345944T1 (pl)
SK (1)	SK287356B6 (pl)
TW (1)	TWI286137B (pl)
WO (1)	WO2002046196A1 (pl)
ZA (1)	ZA200304296B (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6867305B2 (en)	1996-12-03	2005-03-15	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto and analogues thereof
WO1999001124A1 (en)	1996-12-03	1999-01-14	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6204388B1 (en)	1996-12-03	2001-03-20	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto and analogues thereof
US6194181B1 (en) *	1998-02-19	2001-02-27	Novartis Ag	Fermentative preparation process for and crystal forms of cytostatics
US20020058286A1 (en) *	1999-02-24	2002-05-16	Danishefsky Samuel J.	Synthesis of epothilones, intermediates thereto and analogues thereof
GB0029895D0 (en) *	2000-12-07	2001-01-24	Novartis Ag	Organic compounds
DE60330407D1 (de) *	2002-08-23	2010-01-14	Sloan Kettering Inst Cancer	Synthese von Epothilonen, Zwischenprodukte davon, Analoga und ihre Verwendung
US6921769B2 (en)	2002-08-23	2005-07-26	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto and analogues thereof
US7649006B2 (en)	2002-08-23	2010-01-19	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto and analogues thereof
BRPI0314133A8 (pt)	2002-09-23	2017-09-19	Bristol Myers Squibb Co	Processo para isolamento de epotilona b, métodos para cultivo de microorganismo que produza epotilona a ou b e para purifiação de apotilona
FR2846520B1 (fr)	2002-11-06	2006-09-29	Roquette Freres	Utilisation de maltodextrines branchees comme liants de granulation
KR100681811B1 (ko) *	2005-03-15	2007-02-12	성균관대학교산학협력단	생물학적 대사부산물의 효율적인 제거를 통한 유용 이차대사산물의 제조방법
US8178566B2 (en)	2006-08-16	2012-05-15	Novartis Ag	Crystal form of epothilone B and use in pharmaceutical compositions
WO2009100571A1 (zh)	2008-02-01	2009-08-20	Zhejiang Hisun Pharmaceutical Co., Ltd.	一种分离和提纯埃博霉素的方法
AU2011255647A1 (en)	2010-05-18	2012-11-15	Cerulean Pharma Inc.	Compositions and methods for treatment of autoimmune and other diseases
KR101372563B1 (ko)	2011-12-26	2014-03-14	주식회사 삼양바이오팜	에포틸론 함유물질로부터 에포틸론 ａ와 ｂ의 추출 및 정제 방법
CN110964029B (zh) *	2019-12-19	2020-11-03	鲁南制药集团股份有限公司	一种埃博霉素b发酵液的预处理方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE4138042C2 (de) *	1991-11-19	1993-10-14	Biotechnolog Forschung Gmbh	Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
EP0923583A1 (de) *	1996-08-30	1999-06-23	Novartis AG	Verfahren zur herstellung von epothilonen und zwischenprodukte innerhalb des verfahrens
DK1367057T3 (da) *	1996-11-18	2009-01-19	Biotechnolog Forschung Gmbh	Epothiloner E og F
US6384230B1 (en) *	1997-07-16	2002-05-07	Schering Aktiengesellschaft	Thiazole derivatives, method for their production and use
US6365749B1 (en) *	1997-12-04	2002-04-02	Bristol-Myers Squibb Company	Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
US6194181B1 (en) *	1998-02-19	2001-02-27	Novartis Ag	Fermentative preparation process for and crystal forms of cytostatics
DE19826988A1 (de) *	1998-06-18	1999-12-23	Biotechnolog Forschung Gmbh	Epothilon-Nebenkomponenten
EP1652926B1 (en) *	2000-04-28	2009-09-30	Kosan Biosciences, Inc.	Crystalline epothilone d
GB0029895D0 (en) *	2000-12-07	2001-01-24	Novartis Ag	Organic compounds

2000
- 2000-12-07 GB GBGB0029895.0A patent/GB0029895D0/en not_active Ceased
2001
- 2001-11-28 PE PE2001001192A patent/PE20020568A1/es not_active Application Discontinuation
- 2001-12-03 TW TW090129838A patent/TWI286137B/zh not_active IP Right Cessation
- 2001-12-05 PT PT01994791T patent/PT1345944E/pt unknown
- 2001-12-05 SK SK689-2003A patent/SK287356B6/sk not_active IP Right Cessation
- 2001-12-05 CN CNB018201415A patent/CN1263761C/zh not_active Expired - Fee Related
- 2001-12-05 RU RU2003119659/04A patent/RU2285007C2/ru not_active IP Right Cessation
- 2001-12-05 CZ CZ20031565A patent/CZ301664B6/cs not_active IP Right Cessation
- 2001-12-05 EP EP01994791A patent/EP1345944B1/en not_active Expired - Lifetime
- 2001-12-05 PL PL361884A patent/PL209406B1/pl not_active IP Right Cessation
- 2001-12-05 JP JP2002547933A patent/JP4287650B2/ja not_active Expired - Fee Related
- 2001-12-05 DE DE60109814T patent/DE60109814T2/de not_active Expired - Lifetime
- 2001-12-05 HU HU0302579A patent/HU224910B1/hu not_active IP Right Cessation
- 2001-12-05 AR ARP010105667A patent/AR031902A1/es active IP Right Grant
- 2001-12-05 MX MXPA03005097A patent/MXPA03005097A/es active IP Right Grant
- 2001-12-05 AU AU2002224936A patent/AU2002224936B2/en not_active Ceased
- 2001-12-05 IL IL15608801A patent/IL156088A0/xx active IP Right Grant
- 2001-12-05 WO PCT/EP2001/014771 patent/WO2002046196A1/en not_active Ceased
- 2001-12-05 MY MYPI20015563A patent/MY128409A/en unknown
- 2001-12-05 AT AT01994791T patent/ATE292132T1/de active
- 2001-12-05 KR KR1020037007114A patent/KR100894990B1/ko not_active Expired - Fee Related
- 2001-12-05 ES ES01994791T patent/ES2239687T3/es not_active Expired - Lifetime
- 2001-12-05 NZ NZ526197A patent/NZ526197A/en not_active IP Right Cessation
- 2001-12-05 DK DK01994791T patent/DK1345944T3/da active
- 2001-12-05 BR BR0115991-7A patent/BR0115991A/pt not_active IP Right Cessation
- 2001-12-05 CA CA2433414A patent/CA2433414C/en not_active Expired - Fee Related
- 2001-12-05 US US10/433,808 patent/US6946561B2/en not_active Expired - Fee Related
- 2001-12-05 SI SI200130358T patent/SI1345944T1/sl unknown
- 2001-12-05 AU AU2493602A patent/AU2493602A/xx active Pending
2003
- 2003-05-22 IL IL156088A patent/IL156088A/en not_active IP Right Cessation
- 2003-06-02 ZA ZA200304296A patent/ZA200304296B/en unknown
- 2003-06-03 EC EC2003004641A patent/ECSP034641A/es unknown
- 2003-06-06 NO NO20032591A patent/NO329164B1/no not_active IP Right Cessation
2005
- 2005-08-17 US US11/205,892 patent/US7569698B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
MXPA03005097A (es)	2003-09-05
US20050288514A1 (en)	2005-12-29
HUP0302579A3 (en)	2004-10-28
DK1345944T3 (da)	2005-05-30
US6946561B2 (en)	2005-09-20
PE20020568A1 (es)	2002-07-22
JP4287650B2 (ja)	2009-07-01
DE60109814D1 (de)	2005-05-04
US20040054188A1 (en)	2004-03-18
TWI286137B (en)	2007-09-01
WO2002046196A1 (en)	2002-06-13
PT1345944E (pt)	2005-08-31
IL156088A (en)	2008-08-07
NO20032591L (no)	2003-06-06
SK287356B6 (sk)	2010-08-09
HUP0302579A2 (hu)	2003-11-28
HK1059618A1 (en)	2004-07-09
SK6892003A3 (en)	2004-01-08
NO20032591D0 (no)	2003-06-06
ATE292132T1 (de)	2005-04-15
NZ526197A (en)	2005-01-28
CA2433414A1 (en)	2002-06-13
KR100894990B1 (ko)	2009-04-24
EP1345944B1 (en)	2005-03-30
CN1263761C (zh)	2006-07-12
PL361884A1 (pl)	2004-10-04
CN1479741A (zh)	2004-03-03
GB0029895D0 (en)	2001-01-24
IL156088A0 (en)	2003-12-23
HU224910B1 (en)	2006-04-28
ES2239687T3 (es)	2005-10-01
AR031902A1 (es)	2003-10-08
US7569698B2 (en)	2009-08-04
AU2002224936B2 (en)	2005-09-22
EP1345944A1 (en)	2003-09-24
JP2004521879A (ja)	2004-07-22
CZ301664B6 (cs)	2010-05-19
MY128409A (en)	2007-01-31
AU2493602A (en)	2002-06-18
ZA200304296B (en)	2004-04-23
KR20030053535A (ko)	2003-06-28
DE60109814T2 (de)	2006-02-16
RU2285007C2 (ru)	2006-10-10
SI1345944T1 (sl)	2005-12-31
PL209406B1 (pl)	2011-08-31
CA2433414C (en)	2011-01-25
CZ20031565A3 (cs)	2003-10-15
ECSP034641A (es)	2003-07-25
BR0115991A (pt)	2004-01-13

Legal Events

Date	Code	Title	Description
2014-07-21	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
NO329164B1 (no)	2010-09-06	Fremgangsmate for a desorbere, isolere og opparbeide epotiloner og anvendelse av svakt polare eller apolare losemidler for desorpsjon av epotiloner
AU2002224936A1 (en)	2002-08-22	Process for the isolation and purification of epothilones
NO321596B1 (no)	2006-06-06	Fremgangsmate for separasjon av epotiloner
JP2010509317A (ja)	2010-03-25	純粋な形態のラパマイシンならびにこの回収方法および精製方法
CN101918400A (zh)	2010-12-15	一种分离和提纯埃博霉素的方法
WO2014102834A2 (en)	2014-07-03	Process for lurasidone
HK1059618B (en)	2005-10-14	Process for the isolation and purification of epothilones
CN103073624B (zh)	2016-02-24	一种高纯度环孢菌素a衍生物的制备方法
CN105111286A (zh)	2015-12-02	一种高效制备纽莫康定b0的方法
KR100859670B1 (ko)	2008-09-23	타크로리무스를 고수율 및 고순도로 정제하는 방법
US20110034686A1 (en)	2011-02-10	Process for Isolation and Purification of Geldanamycin
KR101372563B1 (ko)	2014-03-14	에포틸론 함유물질로부터 에포틸론 ａ와 ｂ의 추출 및 정제 방법
KR20080039970A (ko)	2008-05-07	식물 유래의 지지체 상에서의 타크롤리무스 정제 방법
RU2745293C1 (ru)	2021-03-23	Способ получения кристаллической формы 8 софосбувира (варианты)
WO2007013017A1 (en)	2007-02-01	A process for purification of macrolides
CN110713478A (zh)	2020-01-21	鲁比前列酮(lubiprostone)晶体以及其制备方法